AKL Research & Development Limited

"AKLRD, a UK SME, is seeking funding to take APPA, a new drug for treating Osteoarthritis (OA), through proof of concept clinical testing. OA, a degenerative joint disease, leads to increasing immobility, chronic pain and ultimately costly joint replacement. In the UK, 8.75 million people have sought treatment for OA and it is a growing problem linked to ...

AKL, a UK SME, has developed a novel therapeutic, APPA, for the treatment of osteoarthritis, a growing chronic disease affecting more than 8.5m people in the UK. It intends to use its innovation voucher to underpin the manufacture and production of APPA.